300412 Zhejiang Canaan Technology
- 3.27
- -0.08-2.39%
Zhejiang Canaan Technology News
zhejiang canaan technology (300412.SZ): The actual controller Fang Hengzhi intends to increase shareholding by 1 million-2 million shares of the company's stock.
On September 3rd, Geelonghui announced that the company recently received a letter of notification titled "Notice of Shareholding Increase Plan" from Mr. Fang Hongzhi, the actual controller of Zhejiang Canaan Technology (300412.SZ). Based on his confidence in the company's future development prospects and recognition of its investment value, Mr. Fang Hongzhi plans to increase his shareholding in the company through centralized bidding using his own or self-raised funds within six months from the date of this announcement. The number of shares to be increased this time shall not be less than 1 million shares and shall not exceed 2 million shares, in order to promote the company's continuous stable and healthy development and enhance investor confidence.
Zhejiang Canaan Technology Limited (SZSE:300412) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
Zhejiang Canaan Technology: Half-year report for the year 2024.
Zhejiang Canaan Technology: Summary of Half-Year Report in 2024.
As of August 9, 2024, the number of shareholders in zhejiang canaan technology (300412.SZ) was 27,683.
As of August 9, 2024, there were 27,683 shareholders of Zhejiang Canaan Technology (300412.SZ), as stated on the investor interaction platform of the company.
As of July 31, 2024, there were 27,983 shareholders of zhejiang canaan technology (300412.SZ) company.
As of July 31st, 2024, there are 27,983 shareholders in Zhejiang Canaan Technology (300412.SZ) according to the company's investor platform.
Zhejiang Canaan Technology (300412.SZ): the company's clients include Tasly Pharmaceutical Group, China Resources, etc.
On August 8th, Gelunhui reported that Zhejiang Canaan Technology (300412.SZ) stated on their investor interaction platform that the majority of their customers are well-known international and domestic companies in the pharmaceutical industry, including Tasly Pharmaceutical Group and China Resources.
As of July 19, the shareholder count of Zhejiang Canaan Technology (300412.SZ) reached 27,136.
On July 22, Gelunhui reported that as of July 19, 2024, there were 27,136 shareholders in Zhejiang Canaan Technology (300412.SZ) according to the investor interaction platform.
Zhejiang Canaan Technology (300412.SZ): The actual controller Fang Hengzhi has completed shareholding of 1.5 million shares.
On July 10th, Gelon Hui reported that Zhejiang Canaan Technology (300412.SZ) received a notice from its actual controller, Mr. Fang Hengzhi, that he increased his shareholding in the company by 1.5 million shares through centralized bidding from July 8th to 9th, 2024. The shareholding plan has been completed.
As of June 28th, the shareholder count of Zhejiang Canaan Technology (300412.SZ) was 27,486.
As of June 28, 2024, there were 27,486 shareholders of Zhejiang Canaan Technology (300412.SZ) on the investor interaction platform.
Zhejiang Canaan Technology (300412.SZ): The actual controller Fang Hengzhi plans to increase shareholding by no less than 1 million shares.
On June 24, GeLonghui reported that Zhejiang Canaan Technology (SZ:300412) announced that it has received a "Notice of Shareholding Increase Plan" issued by its actual controller, Mr. Fang Hengzhi. Based on his confidence in the company's future development prospects and recognition of the company's investment value, in order to promote the continuous and stable development of the company, enhance investor confidence, Mr. Fang Hengzhi plans to use his own or self-raised funds to increase the company's shareholding through centralized bidding within 6 months from the date of this announcement, and the number of shares to be increased this time is not less than 1 million shares.
Canaan Technology (300412.SZ): Net loss of 5.9875 million yuan in the first quarter
Gelonghui, April 26 | Canaan Technology (300412.SZ) released its report for the first quarter of 2024. Operating revenue for the reporting period was 219 million yuan, up 9.54% year on year; net profit attributable to shareholders of listed companies - 5.9875 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 6.6538 million yuan; basic earnings per share - 0.01 yuan.
Canaan Technology (300412.SZ): net loss of 23.43 million yuan in 2023, year-on-year loss reduction
Glonghui, April 19 | Canaan Technology (300412.SZ) released its 2023 annual report. Operating income was 1,047 million yuan, down 5.11% year on year, net loss of 23.43 million yuan, year-on-year loss reduced. After deducting non-net loss of 37.67 million yuan, year-on-year loss reduction, with basic earnings per share -0.05 yuan.
Canaan Technology (300412.SZ): Plans to reform the shareholding subsidiary Shanghai Kaixian and apply for listing on the New Third Board
Gelonghui, March 28 | Canaan Technology (300412.SZ) announced that the company's holding subsidiary Shanghai Kaixian Fluid Technology Co., Ltd. (“Shanghai Kaixian”) plans to restructure and establish a limited company in order to seize capital market development opportunities, increase sustainable development capabilities, and further improve the standardized operation level of the enterprise, and apply for listing in the national SME share transfer system (“New Third Board” for short) in accordance with relevant national laws, regulations, policies and conditions.
Canaan Technology (300412.SZ): The main business is pharmaceutical equipment, and it is a well-known domestic supplier of integrated solutions for smart solid preparation factories
Gelonghui March 22丨Canaan Technology (300412.SZ) said on the investor interactive platform that the company's main business is pharmaceutical equipment and is a well-known domestic supplier of integrated solutions for smart solid pharmaceutical factories. The company's specific business segments can be subdivided into oral solid preparation equipment and smart factory business, biological and sterile preparation water equipment and dispensing system engineering business, smart logistics business, pharmaceutical R&D services, etc.; the products mainly include powder process equipment, solid preparation equipment, traditional Chinese medicine extraction equipment, fluid process equipment, intelligent logistics systems, pharmaceutical R&D consistency evaluation and testing services, etc.
Canaan Technology (300412.SZ): Committed to providing global pharmaceutical customers with integrated automated, intelligent and information-based solutions
Gelonghui March 11 | Canaan Technology (300412.SZ) said on the investor interactive platform that Zhejiang Wantu Sirui Robotics Co., Ltd., the holding company established by the company in November 2022, mainly operates in the intelligent robot business, and the company will rationally plan R&D and investment according to market development and business needs. The company has always maintained its focus on cutting-edge technologies such as artificial intelligence and robotics, hoping to use new technology to explore new scenarios, continuously optimize product systems, and enhance product competitiveness. The company is committed to providing global pharmaceutical customers with integrated automated, intelligent and information-based solutions.
Zhejiang Canaan Technology Limited (SZSE:300412) Surges 42% Yet Its Low P/S Is No Reason For Excitement
Canaan Technology (300412.SZ): Plans to rent out some of its properties
Gelonghui March 1 | Canaan Technology (300412.SZ) announced that the company's new industrial parks have been completed and put into use, and the company will also move to the new industrial park one after another. The original factory company will integrate internal real estate resources and adjust the industrial layout of the supply chain. In order to improve the overall operating efficiency of assets and increase profits, the company's management decided to rent out some of the vacant properties to create greater benefits for the company and shareholders. The company held the 17th meeting of the 5th board of directors and the 17th meeting of the 5th board of supervisors on March 1, 2024 to review and pass the “Proposal on Proposed Lease of Some Owned Properties”. book
Canaan Technology (300412.SZ) Performance Report: Net loss of 22.2532 million yuan in 2023
Glonghui, Feb. 28 | Canaan Technology (300412.SZ) announced its 2023 annual performance report. In 2023, the company achieved total operating income of 1,047 billion yuan, down 5.11% from the same period of the previous year; realized total profit of 2,1848,900 yuan, up 74.96% from the same period of the previous year; realized net profit attributable to shareholders of listed companies - 22.2532 million yuan, an increase of 70.41% over the same period last year; realized net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - RMB 32.87.43 million, compared with the same period last year Up 61.50%.
Canaan Technology (300412.SZ): Expected net loss of 19 million yuan to 28 million yuan in 2023
On January 30, GLONGHUI | Canaan Technology (300412.SZ) announced that it expects a net loss of 19 million yuan to 28 million yuan in 2023, deducting non-net loss of 30 million yuan to 39 million yuan, and operating income of 100 million yuan to 115 million yuan. R&D investment in high-end intelligent pharmaceutical equipment technology and products is high, leading to an increase in R&D costs and labor costs, which affects current performance. Due to the impact of the market environment, the gross margin of sales of some products decreased. At the same time, depreciation and amortization of new fixed assets and intangible assets increased the cost of products, resulting in net profit for the company
Analysis
Price Target
No Data
No Data